多基因检测：早期乳腺癌精准治疗关键

张国淳，廖宁

广东省人民医院　

广东省医学科学院

参考文献

1. JAMESON J L, LONGO D L. Precision medicine—personalized. problematic, and promising. N Engl J Med. 2015;372(23):2229-2234.

2. ZURRIDA S, VERONESI U. Milestones in breast cancer treatment. Breast J. 2015;21(1):3-12.

3. MAGNONI F, ACCARDO G, ROSSI E, et al. Anatomy is not enough: The crucial role of biology and genetics in AJCC eighth edition of the TNM classification for breast cancer. Ann Transl Med. 2019;7(1S):S34.

4. GOLDHIRSCH A, WOOD W C, COATES A S, et al. Strategies for subtypes—dealing with the diversity of breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22(8):1736-1747.

5. KOHLER B A, SHERMAN R L, HOWLADER N, et al. Annual report to the nation on the status of cancer. 1975-2011;featuring incidence of breast cancer subtypes by race/ethnicity. poverty. and state. J Natl Cancer Inst. 2015;107(6):djv048.

6. PAIK S, SHAK S, TANG G, et al. A multigene assay to predict recurrence of Tamoxifen-treated. node-negative breast cancer. N Engl J Med. 2004;351(27):2817-2826.

7. CARDOSO F, van't VEER L J, BOGAERTS J, et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375(8):717-729.

8. FILIPITS M, RUDAS M, JAKESZ R, et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res. 2011;17(18):6012-6020.

9. ZHANG Y, SCHNABEL C A, SCHROEDER B E, et al. Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early-and late-distant recurrence. Clin Cancer Res. 2013;19(15):4196-4205.

10. LAENKHOLM A V, JENSEN M B, ERIKSEN J O, et al. PAM50 risk of recurrence score predicts 10-year distant recurrence in a comprehensive Danish cohort of postmenopausal women allocated to 5 years of endocrine therapy for hormone receptor-positive early breast cancer. J Clin Oncol. 2018;36(8):735-740.

11. National Comprehensive Cancer Network. NCCN clinical practice guidelines in Breast Cancer.V1.2018. www.nccn.org

12. AMIN M B, EDGE S B, GREENE F L, et al. AJCC (American Joint Committee on Cancer) Cancer Staging Manual (8th edition). Chicago: Springer International Publishing, 2017.

13. 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)乳腺癌临床诊疗指南(2019). 北京:人民卫生出版社. 2019.

14. SPARANO J A, GRAY R J, MAKOWER D F, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111-121.

15. HOCHHEISER L, HORNBERGER J, TURNER M, et al. Multi-gene assays: Effect on chemotherapy use, toxicity and cost in estrogen receptor-positive early stage breast cancer. J Comp Eff Res. 2019;8(5):289-304.

通讯作者：廖宁, [e-mail]

原文参见：循证医学. 2019;19(3):133-135.